In vitro activity of moxifloxacin against community respiratory pathogens in Qatar.
Sittana Shamseldin
SS
Elshafie
Jameela
J
Al-Kuwari
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001372:Aza Compounds / Q000494:pharmacology*; D024841:Fluoroquinolones; D006193:Haemophilus influenzae / Q000187:drug effects*; D008826:Microbial Sensitivity Tests; D001936:Moraxella catarrhalis / Q000187:drug effects*; D000077266:Moxifloxacin; D010403:Penicillin Resistance; D011780:Qatar; D011804:Quinolines / Q000494:pharmacology*; D012141:Respiratory Tract Infections / Q000382:microbiology*; D013296:Streptococcus pneumoniae / Q000187:drug effects*; D001618:beta-Lactamases / Q000032:analysis
D000900:Anti-Bacterial Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D001618:beta-Lactamases; D000077266:Moxifloxacin